The combination of immunotherapy for the first time cured pancreatic cancer


Scientists also noted the lack of recurrence after treatment. If clinical studies starting later this year will show a similar effect, this discovery will drastically change the situation for patients with the pancreatic tumor.

Pancreatic cancer is considered one of the most fatal types of cancer. Although chemotherapy can show a good result, the tumor is able to quickly form resistance to treatment. More progressive methods for the treatment of cancer, such as immunotherapy, have not yet shown the necessary therapeutic efficacy. Now scientists have come up with how to fix it. Results of their work

Immunotherapy using PD-1 / PD-L1 control points inhibitors is aimed at helping T-cells in the attack on the tumor. For example, for the treatment of melanoma and tumors of the lungs, it was already possible to achieve good results, but in the therapy of the tumor of the pancreas, it was not possible to achieve. Scientists suggested that with this type of tumor, it is possible that there is a different «braking» system other than PD-1 / PD-L1, turning off T cells.

Preclinical experiments confirmed their hypothesis. It turned out that in the pancreatic cancer, the PD-L1 protein was not expressed at a high level. Instead, scientists identified CD155 protein activating Tigit T-cell receptor.

«The CD155 / TIGIT axis operates similarly to the already known PD-1 / PD-L1 and serves as a brake for these cells (pancreatic cancer),» Commented on William Fried pastor co-author.

Further experiments have shown that the CD40 antibody in combination with the PD-1 inhibitor and the Tigit inhibitor gives a phenomenal result.

Approximately half of the mice, scientists noted a decrease in tumor growth.

During the current year, scientists plan to test a similar triple method in patients with pancreatic tumor. The availability of treatment can accelerate the fact that each of the treatment components has already been tested separately in humans.

The team also intends to explore which types of pancreatic tumors will be most sensitive to therapy. In addition, they plan to increase the effectiveness of therapy to achieve more significant clinical results.

Recently scientists from Canada also

We tell about the most interesting news and technologies — from the upcoming total automation to alternative energy, from artificial intelligence to the future medicine.

Hayk +